Recent advances in suprachoroidal drug delivery for the treatment of ocular posterior segment diseases
10.3760/cma.j.cn511434-20230404-00149
- VernacularTitle:脉络膜上腔给药治疗眼后节疾病的研究进展
- Author:
Shenzhi LIANG
1
;
Guangming WAN
Author Information
1. 郑州大学第一附属医院眼科，郑州 450052
- Keywords:
Suprachoroidal space;
Ocular posterior segment diseases;
Drug delivery;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(12):1028-1032
- CountryChina
- Language:Chinese
-
Abstract:
The suprachoroidal space is a potential space between the sclera and choroid. Suprachoroidal spacedrug delivery is becoming an applicable method to the ocular posterior segment diseases. Because it targets the choroid, retinal pigment epithelium and retina with high bioavailability and safety, while maintaining low levels elsewhere in the eye. In recent years, new discoveries has been carried out in different areas of interest, such as drug delivery methods, pharmacokinetics and clinical trials. Clinical trials with suprachoroidal space injection of triamcinolone acetonide are executed with promising findings for patients with noninfectious uveitis and diabetic macular edema. Suprachoroidal space triamcinolone acetonide injectable suspension is the first and currently the only agent specifically approved for uveitic macular edema by Food and Drug Administration. Nowadays, many clinical trails with suprachoroidal space drug delivery have been explored, although there are still many risks and uncertainties. With the development of technology in the future, suprachoroidal space drug delivery appears to be a promising treatment modality for ocular posterior segment diseases.
